Keyword: Cambridge, Massachusetts
HiFiBiO Therapeutics has had a busy year, as pacts and raises abound, and it’s showing no signs of slowing down as it gets its checkbook out for an unusual French spinout.
Two months after Sarepta was hit with a clinical hold by the FDA, the rare disease biotech has seen this lifted after sorting out a quality blip.
Surface Oncology’s Detlev Biniszkiewicz and Scott Chappel jumped to MPM Capital as executive partners to help identify oncology startup ventures.
Andrew Cheng took the top spot at Akero Therapeutics, not long after it raised $65 million to push its NASH candidate into phase 2 trials.
Fierce 15 winner Fulcrum Therapeutics has pulled in $80 million in series B as it looks to push on with its lead drug into clinical testing.
RootPath raised $7 million to develop a T-cell therapy platform for cancer treatment that addresses the shortcomings of current technology.
Beijing’s CANbridge Life Sciences, developing Western drug candidates in China and Asia, brought on Pfizer’s May Orfali to be chief medical officer.
Eisai's new drug discovery facility will focus on immune-driven Alzheimer’s and receive more than $100 million to get up and running.
InVivo Therapeutics, which specializes in spinal cord injuries, names Richard Toselli, M.D., as its president and chief executive.
Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.